EODData

MEMBERSHIP REGISTER LOG IN

FRA, 12X1: Anavex Life Sciences Corp

03 Oct 2025
LAST:

7.658

CHANGE:
 0.01		OPEN:
7.658		HIGH:
7.658		ASK:
0.000		VOLUME:
2K
CHG(%):
0.08		PREV:
7.664		LOW:
7.658		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
03 Oct 257.6587.6587.6587.6582K
02 Oct 257.6087.6647.6087.6642K
01 Oct 257.5447.5447.5447.5440
30 Sep 257.2467.2467.2467.2460
29 Sep 257.3247.3247.3247.3242K
26 Sep 257.1587.1587.1587.1582K
25 Sep 257.0727.0727.0727.0722K
24 Sep 257.1067.1067.1067.1062K
23 Sep 257.2907.2907.2907.2902K
22 Sep 257.1587.1587.1587.1582K

COMPANY PROFILE

Name:Anavex Life Sciences Corp
About:Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Sector:Healthcare
Industry:Biotechnology
Address:630 5th Avenue, New York, NY, United States, 10111
Website:https://www.anavex.com
ISIN:US0327973006
LEI:549300K1I5L8COCQ8W36

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:7.49
MA10:7.32
MA20:7.57
MA50:8.29
MA100:8.11
MA200:8.35
STO9:98.99
STO14:98.99
RSI14:37.90
WPR14:-1.01
MTM14:0.11
ROC14:0.01
ATR:0.15
Week High:7.66
Week Low:7.16
Month High:8.72
Month Low:7.07
Year High:13.38
Year Low:4.52
Volatility:16.11